You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Tocriscreen 2.0 Max
Biological Activity for Tocriscreen 2.0 Max
Tocriscreen 2.0 Max is a library of 1280 biologically active compounds from the Tocris catalog. Covers a wide range of pharmacological targets and research areas. Compounds are supplied pre-dissolved in 250 μL 10 mM DMSO solutions. A smaller volume is available as Tocriscreen 2.0 Mini (Cat. No. 7151) and Tocriscreen 2.0 Micro (Cat. No. 7152).
This library replaces the Tocriscreen Plus (Cat. No. 5840).
For more information on the Tocriscreen 2.0 Compound Libraries, please download our informative flyer.
If this library does not suit your needs, please submit your requirements through our Tocriscreen PRO custom compound library service.
Key Format and Product Details for Tocriscreen 2.0 Max
- 96-well racks with Matrix storage tubes & SepraSeal caps
- Compounds arranged 80 per rack with 16 racks per library
- Pre-dissolved in DMSO
- Many compounds are exclusive to Tocris
- Unique library with low overlap
- Full chemical and biological data available
- Exceptional purity
The Tocriscreen 2.0 Compound Library contains bioactive compounds covering a diverse range of molecular targets; 7-TM receptors (GPCRs; 27%), non-kinase enzymes (21%), kinases including enzyme-linked receptors (20%), ion channels (13%), cell biology targets (9%), nuclear receptors (6%), and transporters and other pharmacological targets (5%).
Request Compound List
To request a list of the compounds available in the Tocriscreen 2.0 Max please click the request tile below. Compound lists can be provided in Excel or SD format.
Technical Data for Tocriscreen 2.0 Max
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for Tocriscreen 2.0 Max
References for Tocriscreen 2.0 Max
References are publications that support the biological activity of the product.
Li et al (2011) Generation of iPSCs from mouse fibroblasts with a single gene, Oct4, and small molecules. Cell Research 21 196 PMID: 20956998
Beacham et al (2010) Cell-based potassium ion channel screening using the FluxORTM assay. J.Biomol.Screen. 15 44 PMID: 20208034
Hattori et al (2010) Small-molecule screen identifies reactive oxygen species as key regulators of neutrophil chemotaxis. Proc.Natl.Acad.Sci.USA 107 3546 PMID: 20142487
Li et al (2015) Small-molecule-driven direct reprogramming of mouse fibroblasts into functional neurons. Cell Stem Cell 17 195 PMID: 26253201
Yu et al (2015) Small molecules enhance CRISPR genome editing in pluripotent stem cells. Cell Stem Cell 16 142 PMID: 25658371
If you know of a relevant reference for Tocriscreen 2.0 Max, please let us know.
View Related Products by Target
Keywords: Tocriscreen 2.0 Max, Tocriscreen 2.0 Max supplier, biologically, active, pre-dissolved, DMSO, 250ul, 10mM, solutions, Tocriscreen, Compound, Collections, Screening, Library, Libraries, HTS, HCS, high, throughput, content, 7150, Tocris Bioscience
17 Citations for Tocriscreen 2.0 Max
Citations are publications that use Tocris products. Selected citations for Tocriscreen 2.0 Max include:
Gruber et al (2022) Compounds enhancing human sperm motility identified using a high-throughput phenotypic screening platform. Hum.Reprod. deac007 PMID: 35048946
Gull et al (2022) Screening of chemical libraries using xenopus embryos and tadpoles for phenotypic drug discovery. Cold Spring Harb.Protoc. PMID: 36180216
Sasame et al (2022) HSP90 inhibition overcomes resistance to molecular targeted therapy in BRAFV600E-mutant high-grade glioma. Clin.Cancer Res. 28 2425 PMID: 35344043
Tanaka et al (2021) Pan RAS-binding compounds selected from a chemical library by inhibiting interaction between RAS and a reduced affinity intracellular antibody. Sci Rep 11 1712 PMID: 33462327
Endersby et al (2021) Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma. Sci Transl Med 13 eaba7401 PMID: 33472956
Ehteda et al (2021) Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG. Cell Rep 35 108994 PMID: 33852836
Chen et al (2021) A versatile polypharmacology platform promotes cytoprotection and viability of human pluripotent and differentiated cells Nat.Methods 18 528 PMID: 33941937
Telpoukhovskaia et al (2020) Discovery of small molecules that normalize the transcriptome and enhance cysteine cathepsin activity in progranulin-deficient microglia. Science Reports 10 13688 PMID: 32792571
Tian et al (2020) Discovery and Structure Relationships of Salicylanilide Derivatives as Potent, Non-acidic P2X1 Receptor Antagonists. J Med Chem 63 6164 PMID: 32345019
Xie et al (2020) High-throughput screening identified mitoxantrone to induce death of hepatocellular carcinoma cells with autophagy involvement. Biochem.Biophys.Res.Commun. 521 232 PMID: 31653348
Lake et al (2020) Drug and siRNA screens identify ROCK2 as a therapeutic target for ciliopathies. BioRXiv
Gabriel et al (2019) A library screening strategy combining the concepts of MS binding assays and affinity selection mass spectrometry. Front Chem 7 665 PMID: 31637233
Diamantopoulou et al (2019) Identification of compounds that rescue otic and myelination defects in the zebrafish adgrg6 (gpr126) mutant. Elife 8 e44889 PMID: 31180326
Danthi et al (2019) Identification and Characterization of Inhibitors of a Neutral Amino Acid Transporter, SLC6A19, Using Two Functional Cell-Based Assays. SLAS Discov 24 111 PMID: 30589598
Dittmar et al (2016) Drug Repurposing Screening Identifies Novel Compounds That Effectively Inhibit Toxoplasma gondii Growth. mSphere 1 e00042 PMID: 27303726
Fukuda et al (2016) Tubulin is a molecular target of the Wnt-activating chemical probe. BMC Biochemistry 17 9 PMID: 27207629
Yang et al (2017) Derivation of Pluripotent Stem Cells with In Vivo Embryonic and Extraembryonic Potency. Cell 169 243 PMID: 28388409
Do you know of a great paper that uses Tocriscreen 2.0 Max from Tocris? Please let us know.
Reviews for Tocriscreen 2.0 Max
There are currently no reviews for this product. Be the first to review Tocriscreen 2.0 Max and earn rewards!
Have you used Tocriscreen 2.0 Max?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.